ClinicalTrials.gg
RecruitingNCT06999122Updated Jul 27, 2026

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

An observational study in Stroke and Hemorrhagic Stroke, sponsored by EMVision Medical Devices Ltd. Recruiting at 8 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Primary conditionHemorrhagic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hemorrhagic Stroke
Why
  1. The study's listed conditions name Hemorrhagic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by EMVision Medical Devices Ltd · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Hemorrhagic Stroke with a site in United States — 22 open to participants now, 28 under way, 1 of them phase 3. Hemorrhagic Stroke · United States.

Planned enrollment
9th of 19
300 · median 300
Started
2025
with 6 others
Observational
19 of 76
7 open now
Primary completion
2026-11
later than 6 of 27 live
Registered
66th of 76
by date

Among the 76 studies in Hemorrhagic Stroke with a site in United States, this one is the 9th largest by planned enrollment of the 19 observational ones that give a count, is one of 7 that started in 2025, is one of 19 observational ones, reaches primary completion later than 6 of the 27 other live ones, and was the 66th registered.

Hemorrhagic Stroke

234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.

Browse Hemorrhagic Stroke studies →

Open to participants now

22 of the 76 studies in Hemorrhagic Stroke with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hemorrhagic Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.

EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.

Read the detailed description

This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI.

Any adult with neurological deficit suspected to be stroke shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care.

Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion.

A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel.

The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.

03

Conditions studied

  • Stroke
  • Hemorrhagic Stroke

Browse trials for

04

In context

Hemorrhagic Stroke Reclassified

234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.

This study's planned enrollment of 300 is below the median of 379 across 75 observational studies indexed under Hemorrhagic Stroke.

Browse Hemorrhagic Stroke studies →

Lead sponsor

This is the only study on the registry with EMVision Medical Devices Ltd as lead sponsor.

Compared within Hemorrhagic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

300 subjects across two study arms

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥22 years of age
  2. Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset
  3. The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
  4. CT or MRI brain imaging following clinical evaluation per standard of care
  5. Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -

Exclusion criteria

Exclusion Criteria:

  1. Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
  2. In-patient for a neurological condition prior to suspected stroke onset
  3. In-patient in intensive care unit prior to suspected stroke onset
  4. to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
  5. Presence of any implanted electro-stimulating devices in the head and neck
  6. Presence of any metallic implants in the cranial vault or surrounding bones/tissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)
  7. Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the device
  8. Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)
  9. Unable to lie still for the duration of the scan
  10. Pregnant or breastfeeding
  11. Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intracranial Haemorrhage Group A

    Diagnostic Test: Brain Scan

  • Other Group B

    Group B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions.

    Diagnostic Test: Brain Scan

Interventions

  • Diagnostic testBrain Scan

    The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head. The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.

07

What researchers measure

Primary outcomes

  1. Demonstrate haemorrhage detection sensitivity >80% and specificity >80%

    Time frame: <30 minutes from acute baseline CT/MRI

Secondary outcomes

  1. Demonstrate the time to complete an emu™ Brain Scan is <15 minutes

    Time frame: <30 minutes from acute baseline CT/MRI

  2. Evaluate safety of the device

    Time frame: <30 minutes from acute baseline CT/MRI

  3. Evaluate usability of the device

    Time frame: <30 minutes from acute baseline CT/MRI

  4. Evaluate device deficiencies

    Time frame: <30 minutes from acute baseline CT/MRI

08

Study locations

8 of 8 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 31, 2025
StartActual
Mar 26, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 28, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06999122
Lead sponsor
EMVision Medical Devices Ltd
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Mar 26, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 28, 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

Christian Wight, PhD
Contact
cwight@emvision.com.au
61 (0) 490 109 797
Sadie Burnham
Contact
sburnham@vastrax.com
7742078910
Reade De Leacy, MBBS(Hons) FRANZCR
principal investigator · Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
Angela Dos Santos, PhD
principal investigator · Melbourne Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion